Our data now provide a strong rationale for targeting COX-2 expression in tumour-associated macrophages as a CRC chemoprevention strategy that is unlikely to share the cardiovascular toxicity associated with systemic pharmacological COX-2 inhibition8. The gene discussed is PTGS2; the disease is neoplasm.